research Multiple Sclerosis: Side Effects of Interferon Beta Therapy and Their Management
The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
Search
for
Sort by
Research
30 / 1000+ results 
research Disease Modifying Agent Related Skin Reactions in Multiple Sclerosis: Prevention, Assessment, and Management
The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
research Multiple Sclerosis Disease-Modifying Therapies: Adverse Effect Surveillance and Management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Transient Hair Loss During Treatment with Dimethyl Fumarate for Multiple Sclerosis
Dimethyl-fumarate may cause temporary hair loss.
research Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients
Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
research Skin Complications Associated With Interferon-Beta Treatment In Patients With Multiple Sclerosis, Tehran In 2021
Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
research Multiple Sclerosis and Alopecia Areata: Drug-Induced Alopecia Areata or Coexisting Autoimmune Phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Teriflunomide in Multiple Sclerosis: An Update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Skin Lesions in a Daclizumab-Treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Teriflunomide (Aubagio) for the Treatment of Multiple Sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Teriflunomide: A Novel Oral Treatment for Relapsing Multiple Sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Does Post-Void Residual Volume Predict Worsening Urological Symptoms in Patients with Multiple Sclerosis?
Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
research Erosive Pustular Dermatosis of the Scalp and Multiple Sclerosis: Just a Coincidence?
EPDS and MS might share an immune-related cause.
research Alemtuzumab-Induced Secondary Autoimmune Skin Disorders as Side Effects of Multiple Sclerosis Therapy: Problem That Can Be Influenced or Fate? A Narrative Overview of the Literature and a Neuroprotective Role of Vitamin D
Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
research Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Teriflunomide Efficacy, Safety, and Tolerability in Patients with Relapsing Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide was approved by the US FDA in 2012 for treating relapsing forms of multiple sclerosis (RMS) based on Phase II and III trials, including TEMSO, TOWER, and TOPIC. The 14 mg dose significantly reduced the annualized relapse rate and risk of disability progression, while the 7 mg dose also reduced relapse rates but not disability progression. MRI measures showed reduced lesion activity with both doses. Safety data indicated common adverse events like headache, alopecia, and nausea. Teriflunomide was considered an effective treatment option for RMS, with specific precautions for women of childbearing potential.
research Wider Clinical Applications of Fumaric Acid Esters: A Useful Option in Psoriasis Patients with Multiple Sclerosis
Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
research Pooled Safety and Tolerability Data from Four Placebo-Controlled Teriflunomide Studies and Extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research Editors' Picks
Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.
research Numerical Methods for Decision-Making in Clinical Care: Where to Now?
Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research Alopecia Areata After Severe Allergic Contact Dermatitis to a Permanent Hair Dye
Severe allergic reactions to hair dye can trigger hair loss and may be linked to multiple sclerosis.
research Clinical Snippets: Research Findings in Dermatology
New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.
research Clinical Snippets: Insights into Dermatological Studies
Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.
research Azathioprine
Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.